We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+22.96%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.54B
AUM Growth
+$187M
Cap. Flow
-$12.7M
Cap. Flow %
-0.82%
Top 10 Hldgs %
46.64%
Holding
69
New
11
Increased
6
Reduced
41
Closed
4

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$42M
2
ZGNX
Zogenix, Inc.
ZGNX
+$25.5M
3
TSRO
TESARO, Inc.
TSRO
+$24.7M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$14.8M
5
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$12.1M

Top Sells

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$18.2M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$15.1M
3
QTRX icon
Quanterix
QTRX
+$12.5M
4
BPMC
Blueprint Medicines
BPMC
+$11.8M
5
MTVA
MetaVia Inc
MTVA
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
$22.4M 1.46%
734,588
-200,000
-21% -$5.87M
NBIX icon
27
Neurocrine Biosciences
NBIX
$16.4B
$21.5M 1.4%
175,000
-16,112
-8% -$1.83M
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$6.09B
$21.2M 1.38%
831,000
– –
TSRO
29
CALL
DELISTED
TESARO, Inc.
TSRO
$19.5M 1.27%
+500,000
New +$17.7M
ARNA
30
DELISTED
Arena Pharmaceuticals Inc
ARNA
$18.9M 1.23%
410,000
-40,000
-9% -$1.62M
INCY icon
31
Incyte
INCY
$24.3B
$18M 1.17%
260,000
+60,000
+30% +$4.12M
ZLAB icon
32
Zai Lab
ZLAB
$2.07B
$15.7M 1.02%
808,166
+475,000
+143% +$10.3M
ARGX icon
33
argenx
ARGX
$54.3B
$14.4M 0.94%
190,000
-88,536
-32% -$7.85M
INSP icon
34
Inspire Medical Systems
INSP
$1.73B
$12.6M 0.82%
300,000
-25,000
-8% -$1.17M
ZGNX
35
CALL
DELISTED
Zogenix, Inc.
ZGNX
$12.4M 0.81%
+250,000
New +$12.7M
BHVN
36
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.76M 0.63%
260,000
-24,735
-9% -$910K
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$9.12M 0.59%
600,000
-68,743
-10% -$1.05M
RUBY
38
DELISTED
Rubius Therapeutics, Inc
RUBY
$8.75M 0.57%
+364,559
New +$8.34M
CNST
39
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$8.56M 0.56%
+1,271,687
New +$12.1M
SPPI
40
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$8.4M 0.55%
500,000
-700,000
-58% -$15.1M
AMRN
41
Amarin Corp
AMRN
$302M
$8.13M 0.53%
+25,000
New +$1.89M
NERV icon
42
Minerva Neurosciences
NERV
$203M
$7.63M 0.5%
75,988
– –
REPL icon
43
Replimune Group
REPL
$994M
$7.53M 0.49%
+467,792
New +$8.2M
ACRS icon
44
Aclaris Therapeutics
ACRS
$888M
$7.26M 0.47%
500,000
-25,538
-5% -$438K
ABEO icon
45
Abeona Therapeutics
ABEO
$388M
$6.4M 0.42%
20,000
-1,976
-9% -$701K
CFRX
46
DELISTED
ContraFect Corporation
CFRX
$6.21M 0.4%
3,750
-490
-12% -$811K
SRRK icon
47
Scholar Rock
SRRK
$5.74B
$5.41M 0.35%
210,078
– –
HRTX icon
48
Heron Therapeutics
HRTX
$95.5M
$5.38M 0.35%
170,000
-21,108
-11% -$786K
YMAB
49
DELISTED
Y-mAbs Therapeutics
YMAB
$5.31M 0.35%
+200,000
New +$5.09M
BOLD
50
DELISTED
Audentes Therapeutics, Inc
BOLD
$4.95M 0.32%
125,000
-197,945
-61% -$7.38M
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Cormorant Asset Management held 69 positions worth $1.54B, up 14% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q3 2018 filing shows 11 new, 6 increased, 41 reduced and 4 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,486,898 shares worth $43.4M. The largest sale was Vanda Pharmaceuticals, an estimated $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier.

  • Cormorant Asset Management's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,486,898 shares worth $43.4M.
  • Cormorant Asset Management added most to TESARO, Inc. in Q3 2018, an estimated $24.7M increase.
  • Cormorant Asset Management's biggest Q3 2018 reduction was Spectrum Pharmaceuticals Inc, cutting an estimated $15.1M.
  • Cormorant Asset Management fully exited Vanda Pharmaceuticals in Q3 2018, selling an estimated $18.2M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2018.
  • Cormorant Asset Management opened 11 new positions and closed 4 in Q3 2018.
  • Cormorant Asset Management's portfolio value rose 14% quarter-over-quarter to $1.54B.

Based on Cormorant Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.